BRPI0809663A8 - Composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado. - Google Patents

Composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.

Info

Publication number
BRPI0809663A8
BRPI0809663A8 BRPI0809663A BRPI0809663A BRPI0809663A8 BR PI0809663 A8 BRPI0809663 A8 BR PI0809663A8 BR PI0809663 A BRPI0809663 A BR PI0809663A BR PI0809663 A BRPI0809663 A BR PI0809663A BR PI0809663 A8 BRPI0809663 A8 BR PI0809663A8
Authority
BR
Brazil
Prior art keywords
live
atenuated
inactivation
reducing
virus
Prior art date
Application number
BRPI0809663A
Other languages
English (en)
Inventor
T Stinchcomb Dan
E Osorio Jorge
Wiggan O'neil
Original Assignee
Inviragen Inc
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39827288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0809663(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inviragen Inc, Takeda Vaccines Inc filed Critical Inviragen Inc
Publication of BRPI0809663A2 publication Critical patent/BRPI0809663A2/pt
Publication of BRPI0809663A8 publication Critical patent/BRPI0809663A8/pt
Publication of BRPI0809663B1 publication Critical patent/BRPI0809663B1/pt
Publication of BRPI0809663B8 publication Critical patent/BRPI0809663B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composição de Vírus Vivo Atenuado, Método de Diminuição da Inativação de Composição de Vírus Vivo Atenuado, Uso e Kit Respectivos As modalidades aqui relacionam-se com composições e métodos para vírus vivos. Em certas modalidades, uma composição de vírus vivo atenuado inclui, mas, sem uma limitação, um ou mais vírus vivos atenuados e composições para reduzir a inativação e/ou a degradação do vírus vivo atenuado. Em outras modalidades, a composição de vírus vivo atenuado pode ser uma composição de vacina. Ainda em outras composições, uma composição de vírus vivo atenuado pode incluir pelo menos um carboidrato, pelo menos uma proteína e pelo menos uma surfatante de peso molecular elevado para reduzir a inativação e/ou a degradação do vírus vivo atenuado.
BRPI0809663A 2007-04-06 2008-04-04 composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado. BRPI0809663B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91057907P 2007-04-06 2007-04-06
US60/910,579 2007-04-06
PCT/US2008/059472 WO2009014774A1 (en) 2007-04-06 2008-04-04 Methods and compositions for live attenuated viruses

Publications (4)

Publication Number Publication Date
BRPI0809663A2 BRPI0809663A2 (pt) 2014-10-14
BRPI0809663A8 true BRPI0809663A8 (pt) 2017-07-11
BRPI0809663B1 BRPI0809663B1 (pt) 2020-02-11
BRPI0809663B8 BRPI0809663B8 (pt) 2021-05-25

Family

ID=39827288

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809663A BRPI0809663B8 (pt) 2007-04-06 2008-04-04 composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.

Country Status (28)

Country Link
US (4) US8084039B2 (pt)
EP (2) EP2144998B1 (pt)
JP (4) JP5296775B2 (pt)
KR (4) KR20150082667A (pt)
CN (4) CN104998257A (pt)
AU (1) AU2008279576C1 (pt)
BR (1) BRPI0809663B8 (pt)
CA (1) CA2720570C (pt)
CO (1) CO6260150A2 (pt)
CU (1) CU20090169A7 (pt)
CY (1) CY1118958T1 (pt)
DK (1) DK2144998T3 (pt)
ES (1) ES2621511T3 (pt)
HK (1) HK1217168A1 (pt)
HR (1) HRP20170513T1 (pt)
HU (1) HUE031617T2 (pt)
IL (3) IL201429A (pt)
LT (1) LT2144998T (pt)
MX (2) MX360728B (pt)
MY (3) MY180465A (pt)
NZ (2) NZ600958A (pt)
PH (1) PH12015500773A1 (pt)
PL (1) PL2144998T3 (pt)
PT (1) PT2144998T (pt)
SG (2) SG10201508397VA (pt)
SI (1) SI2144998T1 (pt)
WO (1) WO2009014774A1 (pt)
ZA (2) ZA200907790B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2144998T (pt) * 2007-04-06 2017-04-07 Takeda Vaccines Inc Métodos e composições para vírus vivos atenuados
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) * 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
WO2010065911A1 (en) * 2008-12-05 2010-06-10 Inviragen, Inc. Compositions, methods and uses for inducing viral growth
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US20120219590A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
PH12013502442A1 (en) * 2011-05-26 2018-03-21 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine
EP2726606A1 (en) * 2011-06-28 2014-05-07 Leukocare Ag Novel stabilisation method for viruses or bacteria
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
CA2873775C (en) 2012-05-21 2021-04-20 Sanofi Pasteur Limited Herpesvirus compositions and related methods
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP2968515B1 (en) 2013-03-14 2019-05-08 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US10588957B2 (en) 2013-10-25 2020-03-17 Leukocare Ag Method for the production of stabile vaccines
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN103877565A (zh) * 2014-02-24 2014-06-25 黄淮学院 治疗膀胱癌的基因针剂及其制备方法
HUE053624T2 (hu) 2014-11-07 2021-07-28 Sublimity Therapeutics Ltd Ciklosporint tartalmazó készítmények
IL308119B2 (en) * 2014-12-18 2025-11-01 Amgen Inc Stable frozen herpes simplex virus formulation
US20180094280A1 (en) * 2015-03-20 2018-04-05 Bluebird Bio, Inc. Vector formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
TWI569806B (zh) * 2015-06-10 2017-02-11 輔英科技大學 Stabilizer compositions for vaccines and methods for their preparation and swine fever vaccine containing the same
MY200888A (en) 2015-09-30 2024-01-22 Panacea Biotec Ltd Stable Live Attenuated Recombinant Dengue Vaccine
WO2017109698A1 (en) * 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
AR107262A1 (es) * 2016-01-27 2018-04-11 Lilly Co Eli Inactivación de patógenos por delipidación
JP6376578B2 (ja) * 2016-02-18 2018-08-22 学校法人慶應義塾 細胞培養培地、培養方法、及びオルガノイド
EP3442588A4 (en) 2016-04-14 2020-02-19 Trizell Ltd. STABILIZING VIRUS VECTORS
CN105925541A (zh) * 2016-05-13 2016-09-07 云南省畜牧兽医科学院 一种蓝舌病病毒冻存保护剂及冻存方法
TW202309276A (zh) * 2016-08-03 2023-03-01 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
KR102658198B1 (ko) * 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
CN107475204A (zh) * 2017-08-03 2017-12-15 中国人民解放军军事医学科学院军事兽医研究所 一种囊膜病毒保护剂及其制备方法
CN107233576B (zh) * 2017-08-08 2020-02-07 江苏省农业科学院 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
CA3079828A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
BR112020011205A8 (pt) 2017-12-07 2023-02-07 Merck Sharp & Dohme Formulações de composições de vacina contra o vírus da dengue
CA3111273C (en) * 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020113197A1 (en) * 2018-11-30 2020-06-04 Vaccine Stabilization Institute Viral formulations containing amino acids
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
US20210322542A1 (en) * 2020-04-11 2021-10-21 Qiyi Xie Vaccination against coronavirus with poliomyelitis vaccine
JP2022524251A (ja) * 2020-04-11 2022-05-02 チーイー シエ， ポリオワクチンでのコロナウイルスに対するワクチン接種
WO2022037248A1 (en) * 2020-08-19 2022-02-24 Versitech Limited Live attenuated sars-cov-2 virus immunogenic compositions, methods of making and using
EP4598578A1 (en) * 2022-10-07 2025-08-13 Elarex Inc. Stabilization of virus-based therapeutic agent
TW202535439A (zh) * 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
WO1999006068A2 (en) * 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6163606A (en) * 1998-09-16 2000-12-19 Lucent Technologies Inc. System for providing virtual called party identification in a voice mail system
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
CN1433465A (zh) 1999-05-04 2003-07-30 埃里克·爱德华·沃勒尔 保存病毒和支原体的方法
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US7094411B2 (en) * 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
AU2003267943C1 (en) * 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
US8293530B2 (en) 2006-10-17 2012-10-23 Carnegie Mellon University Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
AU2003230908A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1494651A4 (en) * 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
EP1495763B1 (en) 2002-04-15 2009-03-18 Tetsuo Santo Therapeutic cream for dermatitis
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US6873807B2 (en) * 2003-03-20 2005-03-29 Kabushiki Kaisha Toshiba Image forming apparatus
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US7294455B2 (en) 2003-05-16 2007-11-13 The University Of North Carolina At Chapel Hill Fixed-dried platelets cross-linked to protein
WO2005074460A2 (en) * 2003-12-05 2005-08-18 Becton Dickinson And Company Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
WO2005120540A2 (en) * 2004-06-09 2005-12-22 Schering Aktiengesellschaft Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
PT2144998T (pt) * 2007-04-06 2017-04-07 Takeda Vaccines Inc Métodos e composições para vírus vivos atenuados

Also Published As

Publication number Publication date
PL2144998T3 (pl) 2017-07-31
US8084039B2 (en) 2011-12-27
JP5296775B2 (ja) 2013-09-25
MX360728B (es) 2018-11-14
KR20100016294A (ko) 2010-02-12
NZ580978A (en) 2012-07-27
EP2940129A1 (en) 2015-11-04
JP2013209421A (ja) 2013-10-10
HRP20170513T1 (hr) 2017-06-02
KR20180036801A (ko) 2018-04-09
KR101562971B1 (ko) 2015-10-23
EP2144998A4 (en) 2011-11-02
MX2009010798A (es) 2010-02-18
PH12015500773B1 (en) 2017-08-07
IL201429A (en) 2013-09-30
AU2008279576C1 (en) 2014-01-23
AU2008279576B2 (en) 2013-08-22
JP2019172686A (ja) 2019-10-10
HK1217168A1 (zh) 2016-12-30
CU20090169A7 (es) 2012-06-21
PH12015500773A1 (en) 2017-08-07
IL248522A0 (en) 2016-12-29
SI2144998T1 (sl) 2017-05-31
IL228065B (en) 2019-05-30
US20200108136A1 (en) 2020-04-09
ZA200907790B (en) 2014-04-30
CN104083757A (zh) 2014-10-08
MY180465A (en) 2020-11-30
CN110478479A (zh) 2019-11-22
EP2940129B1 (en) 2020-05-06
CA2720570A1 (en) 2009-01-29
ZA201400725B (en) 2022-11-30
CY1118958T1 (el) 2018-01-10
WO2009014774A1 (en) 2009-01-29
EP2144998B1 (en) 2017-01-04
SG10201913741YA (en) 2020-03-30
EP2144998A1 (en) 2010-01-20
US10525120B2 (en) 2020-01-07
MY200568A (en) 2024-01-03
US11197923B2 (en) 2021-12-14
PT2144998T (pt) 2017-04-07
KR20150082667A (ko) 2015-07-15
DK2144998T3 (en) 2017-04-10
KR102134980B1 (ko) 2020-07-16
AU2008279576A1 (en) 2009-01-29
BRPI0809663B8 (pt) 2021-05-25
IL201429A0 (en) 2011-08-01
CN104998257A (zh) 2015-10-28
HUE031617T2 (en) 2017-07-28
CN110478479B (zh) 2024-09-03
HK1140516A1 (en) 2010-10-15
JP6817370B2 (ja) 2021-01-20
NZ600958A (en) 2015-05-29
US20140302091A1 (en) 2014-10-09
KR20170038110A (ko) 2017-04-05
JP2010523127A (ja) 2010-07-15
CA2720570C (en) 2022-10-04
CN101679954A (zh) 2010-03-24
IL228065A0 (en) 2013-09-30
US20080248551A1 (en) 2008-10-09
MY156422A (en) 2016-02-26
IL248522B (en) 2019-11-28
CO6260150A2 (es) 2011-03-22
SG10201508397VA (en) 2015-11-27
BRPI0809663A2 (pt) 2014-10-14
BRPI0809663B1 (pt) 2020-02-11
ES2621511T3 (es) 2017-07-04
LT2144998T (lt) 2017-04-25
US20170100474A1 (en) 2017-04-13
JP2016041753A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
BRPI0809663B8 (pt) composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CO6720961A2 (es) Imidazopiridazinas sustituidas
AR109995A2 (es) Método para inhibir la resorción ósea
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BR112012012476A2 (pt) "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
BR112018007982A2 (pt) composição, reação enzimática e método para preparar um copolímero de enxerto
AR068363A1 (es) Reduccion de infecciones concomitantes en cerdos mediante el uso de antigeno pcv2
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
BR112012032979A2 (pt) composição para limpeza límpida, de baixa irritação, e com ph relativamente baixo
NO20064584L (no) Tetrahydropyridoindolderivater
BRPI0711608B8 (pt) composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
AR071968A1 (es) Uso de un oligosacarido en el tratamiento de la inflamacion intestinal
CR10495A (es) Composicion que comprende por lo menos un alcohol alifatico superior y un extracto de griffonia simplicifolia
BR112022016456A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
BRPI0520330A2 (pt) adjuvante a base de ácido polinosìnico-policitidìlico
BR112013029920A2 (pt) composição de cobertura misturável, cobertura de mistura, uso da composição de cobertura misturável e método para preparar a composição de cobertura misturável
BR112013018745A2 (pt) composições de ácido hialurônico estabilizadas contra o efeito de degradação de calor ou de enzimas
BR112013026153A2 (pt) Composição farmacêutica; uso de pelo menos um éter de celulose não iônico; método parapreparar uma composição farmacêutica; método para tratar e/ou prevenir um distúrbioclimatérico; uso de uma composição farmacêutica; e kit

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TAKEDA VACCINES INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 20110136285, APRESENTADA EM 27/12/2011, E CONSIDERADA COMO PETICAO NAO CONHECIDA, VISTO QUE O REQUERENTE NAO E MAIS O TITULAR DO PEDIDO.

B151 Others concerning applications: resolution cancelled [chapter 15.31 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: INVIRAGEN, INC. (US)

B25G Requested change of headquarter approved

Owner name: INVIRAGEN, INC. (US)

B25A Requested transfer of rights approved

Owner name: TAKEDA VACCINES INC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: TAKEDA VACCINES, INC. (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF